These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27170529)

  • 1. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
    Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
    Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin.
    Schumann C; Chan S; Millar JA; Bortnyak Y; Carey K; Fedchyk A; Wong L; Korzun T; Moses AS; Lorenz A; Shea D; Taratula O; Khalimonchuk O; Taratula O
    Nanomedicine; 2018 Jun; 14(4):1395-1405. PubMed ID: 29635082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression.
    Schumann C; Taratula O; Khalimonchuk O; Palmer AL; Cronk LM; Jones CV; Escalante CA; Taratula O
    Nanomedicine; 2015 Nov; 11(8):1961-70. PubMed ID: 26238076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
    Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
    Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
    Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
    Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.
    Shah V; Taratula O; Garbuzenko OB; Taratula OR; Rodriguez-Rodriguez L; Minko T
    Clin Cancer Res; 2013 Nov; 19(22):6193-204. PubMed ID: 24036854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
    Jiang L; Luo RY; Yang J; Cheng YX
    Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
    Chen J; Adikari M; Pallai R; Parekh HK; Simpkins H
    Cancer Chemother Pharmacol; 2008 May; 61(6):979-87. PubMed ID: 17661040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
    Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Platinum-Maurocalcine Conjugate Induces Apoptosis of Human Glioblastoma Cells by Acting through the ROS-ERK/AKT-p53 Pathway.
    Aroui S; Dardevet L; Ben Ajmia W; de Boisvilliers M; Perrin F; Laajimi A; Boumendjel A; Kenani A; Muller JM; De Waard M
    Mol Pharm; 2015 Dec; 12(12):4336-48. PubMed ID: 26465677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antioxidant protein PARK7 plays an important role in cell resistance to Cisplatin-induced apoptosis in case of clear cell renal cell carcinoma.
    Trivedi R; Dihazi GH; Eltoweissy M; Mishra DP; Mueller GA; Dihazi H
    Eur J Pharmacol; 2016 Aug; 784():99-110. PubMed ID: 27112662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
    Hamad SA; Beale P; Yu JQ; Huq F
    Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.